Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients ( Among the novel therapies, great interest has been aroused by sodiumglucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), that have changed the management of diabetic patients
Slow titration will also help decrease gastrointestinal symptoms that may arise
Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al
The researchers are still optimistic about Retatrutides potential
Some people are more sensitive than others to injections, and different techniques may be of benefit to decrease any discomfort
Is Tirzepatide Right for You